Orthofix Medical Inc. (NASDAQ:OFIX) Receives Average Recommendation of “Hold” from Brokerages

Orthofix Medical Inc. (NASDAQ:OFIX) has received an average recommendation of “Hold” from the six brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $18.25.

OFIX has been the subject of a number of recent research reports. Canaccord Genuity Group cut their price objective on Orthofix Medical from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday. TD Cowen initiated coverage on Orthofix Medical in a research report on Tuesday, January 27th. They set a “hold” rating and a $14.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a report on Thursday, January 22nd. Finally, Barrington Research dropped their price target on Orthofix Medical from $18.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday.

Key Orthofix Medical News

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Engine Capital (a major shareholder) bought shares in two recent transactions — ~124,797 shares at ~$12.55 on Feb. 24 and an additional 13,061 shares at ~$12.96 on Feb. 25 — increasing its stake and signaling confidence from a large institutional holder. Engine Capital purchases OFIX shares
• Neutral Sentiment: Analysts trimmed price targets but kept several constructive ratings: Canaccord cut its target from $24 to $20 (still a “buy”) and others reduced targets modestly; consensus remains mixed (roughly a mid‑teens/$18-ish average target). This lowers upside expectations but does not indicate a broad teardown of the bull case. Analyst notes and price-target changes
• Negative Sentiment: Q4 results missed on EPS: reported ($0.06) vs. $0.44 expected; revenue was roughly in line but margins and ROE were negative — the EPS shortfall triggered investor selling and increased near-term skepticism. Shares down after earnings miss
• Negative Sentiment: Management flagged margin delays and issued revised 2026 guidance that shifts the narrative toward execution risk; until margin recovery and guidance clarity appear, the stock faces headwinds. Narrative shifting: margin delays and guidance

Insider Transactions at Orthofix Medical

In other news, CFO Julie Andrews sold 4,873 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $14.38, for a total transaction of $70,073.74. Following the sale, the chief financial officer owned 58,039 shares in the company, valued at $834,600.82. The trade was a 7.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Massimo Calafiore sold 9,797 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.21, for a total transaction of $149,012.37. Following the completion of the transaction, the chief executive officer directly owned 217,237 shares of the company’s stock, valued at $3,304,174.77. This represents a 4.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 24,270 shares of company stock valued at $370,958 over the last ninety days. Corporate insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Paradigm Capital Management Inc. NY grew its stake in Orthofix Medical by 34.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock valued at $37,248,000 after acquiring an additional 858,900 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Orthofix Medical by 86.6% during the third quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock worth $21,605,000 after purchasing an additional 684,850 shares during the period. Juniper Investment Company LLC grew its position in Orthofix Medical by 23.3% during the fourth quarter. Juniper Investment Company LLC now owns 3,510,333 shares of the medical device company’s stock valued at $53,217,000 after purchasing an additional 663,278 shares in the last quarter. Bank of America Corp DE grew its position in Orthofix Medical by 659.5% during the second quarter. Bank of America Corp DE now owns 687,410 shares of the medical device company’s stock valued at $7,665,000 after purchasing an additional 596,907 shares in the last quarter. Finally, Engine Capital Management LP increased its stake in Orthofix Medical by 13.6% in the 2nd quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock valued at $47,406,000 after buying an additional 510,281 shares during the period. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX opened at $13.53 on Friday. Orthofix Medical has a twelve month low of $10.24 and a twelve month high of $18.66. The company has a current ratio of 2.45, a quick ratio of 1.38 and a debt-to-equity ratio of 0.39. The firm has a 50-day moving average of $14.08 and a two-hundred day moving average of $14.70. The company has a market capitalization of $535.79 million, a price-to-earnings ratio of -5.78 and a beta of 0.78.

Orthofix Medical (NASDAQ:OFIX) last released its earnings results on Tuesday, February 24th. The medical device company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.50). Orthofix Medical had a negative return on equity of 20.38% and a negative net margin of 11.21%.The business had revenue of $219.91 million during the quarter, compared to the consensus estimate of $218.72 million. As a group, analysts expect that Orthofix Medical will post -2.81 earnings per share for the current fiscal year.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.